Top advances of the year: Melanoma
Relatlimab (anti‑LAG‑3) in combination with nivolumab (anti‑PD‑1) doubles median progression‑free survival compared with nivolumab alone in untreated, unresectable melanoma.
These results suggest a new first‑line option for metastatic melanoma, potentially improving long‑term outcomes and reducing exposure to the toxicities associated with combination CTLA‑4 and PD‑1 blockade.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- Melanoma Research
- The Clinical Trial Landscape for Melanoma Therapies